Novinky v léčbě mnohočetného myelomu
| Title in English | The news in multiple myeloma treatment |
|---|---|
| Authors | |
| Year of publication | 2017 |
| Type | Article in Periodical |
| Magazine / Source | Interní medicina pro praxi |
| MU Faculty or unit | |
| Citation | |
| Web | https://www.internimedicina.cz/artkey/int-201701-0005_Novinky_v_lecbe_mnohocetneho_myelomu.php?l=en |
| Keywords | mnohočetný myelom; imunomodulační léky; inhibitory proteasomu; monoklonální protilátky.The news in multiple myeloma treatment |
| Description | Nowadays, the treatment of multiple myeloma is undergoing dynamic development. New antimyeloma drugs – carfilzomib, ixazomib, pomalidomid, daratumumab, elotuzumab and panobinostat – have been tested in cilnical trials. The use of these new drugs is beneficial for patients with relapsed multiple myeloma and primarily can improve prognosis of refractory disease. We expect that many of these drugs will become regular parts of standard medical protocols for relapse and most probably also for the initial treatment. Carfilzomib and pomalidomid have extended the progression free survival almost twice when compared to standard treatment. Also, monoclonal antibodies are a hopeful group of drugs, which show a high efficiency based on a different mechanism of effect than current treatment. The aim of this review is to present results of clinical trials describing use of these new drugs in treatment of multiple myeloma. |